{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stage+1+-+Vehicle&page=2",
    "query": {
      "intervention": "Stage 1 - Vehicle",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stage+1+-+Vehicle&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T02:19:08.291Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00343187",
      "title": "A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rash",
        "Non-small-Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "ACZONE (dapsone) Gel, 5%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2006-06",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2011-05-30",
      "last_synced_at": "2026-09-28T02:19:08.291Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Hershey, Pennsylvania • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00343187"
    },
    {
      "nct_id": "NCT03745638",
      "title": "Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib Cream",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 631,
      "start_date": "2018-12-20",
      "completion_date": "2020-12-01",
      "has_results": true,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-09-28T02:19:08.291Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03745638"
    },
    {
      "nct_id": "NCT01758432",
      "title": "Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "PRT064445/Apixaban",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo/Apixaban",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Portola Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 54,
      "start_date": "2012-12",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2023-08-07",
      "last_synced_at": "2026-09-28T02:19:08.291Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01758432"
    },
    {
      "nct_id": "NCT01844739",
      "title": "A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "NVN1000 4% Gel",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novan, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2013-04",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2018-11-19",
      "last_synced_at": "2026-09-28T02:19:08.291Z",
      "location_count": 1,
      "location_summary": "Broomall, Pennsylvania",
      "locations": [
        {
          "city": "Broomall",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01844739"
    },
    {
      "nct_id": "NCT01454505",
      "title": "Safety and Efficacy of AL-53817 Nasal Spray Solution",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nasal Allergies",
        "Allergies"
      ],
      "interventions": [
        {
          "name": "AL-53817 nasal spray solution",
          "type": "DRUG"
        },
        {
          "name": "Vehicle nasal spray",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2011-10",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2013-05-20",
      "last_synced_at": "2026-09-28T02:19:08.291Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01454505"
    },
    {
      "nct_id": "NCT05757219",
      "title": "Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Itacitinib",
          "type": "DRUG"
        },
        {
          "name": "Chimeric antigen receptor (CAR) T-cell therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2023-05-19",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-09-28T02:19:08.291Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05757219"
    },
    {
      "nct_id": "NCT00589953",
      "title": "High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infant, Premature",
        "Erythropoietin",
        "Brain Injury",
        "Intraventricular Hemorrhage",
        "Periventricular Leukomalacia",
        "Neurodevelopmental Outcomes",
        "Randomized Clinical Trial"
      ],
      "interventions": [
        {
          "name": "Erythropoietin",
          "type": "DRUG"
        },
        {
          "name": "Saline placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Atlantic Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "24 Hours",
        "sex": "ALL",
        "summary": "Up to 24 Hours"
      },
      "enrollment_count": 22,
      "start_date": "2007-07",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2013-07-30",
      "last_synced_at": "2026-09-28T02:19:08.291Z",
      "location_count": 1,
      "location_summary": "Morristown, New Jersey",
      "locations": [
        {
          "city": "Morristown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00589953"
    },
    {
      "nct_id": "NCT02432807",
      "title": "Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bacterial Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Vancomycin 1.1%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kurobe LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 303,
      "start_date": "2015-05",
      "completion_date": "2018-05-31",
      "has_results": true,
      "last_update_posted_date": "2024-10-23",
      "last_synced_at": "2026-09-28T02:19:08.291Z",
      "location_count": 16,
      "location_summary": "Paramount, California • Petaluma, California • Rancho Cordova, California + 13 more",
      "locations": [
        {
          "city": "Paramount",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Rancho Cordova",
          "state": "California"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "Waterloo",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02432807"
    },
    {
      "nct_id": "NCT01123772",
      "title": "Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Health"
      ],
      "interventions": [
        {
          "name": "INO-8875",
          "type": "DRUG"
        },
        {
          "name": "Placebo control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Inotek Pharmaceuticals Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "35 Years to 65 Years"
      },
      "enrollment_count": 70,
      "start_date": "2010-05",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2012-04-30",
      "last_synced_at": "2026-09-28T02:19:08.291Z",
      "location_count": 1,
      "location_summary": "Evansville, Indiana",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01123772"
    },
    {
      "nct_id": "NCT02422797",
      "title": "Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DTG 50 mg",
          "type": "DRUG"
        },
        {
          "name": "RPV 25 mg",
          "type": "DRUG"
        },
        {
          "name": "CAR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 518,
      "start_date": "2015-04-21",
      "completion_date": "2023-05-25",
      "has_results": true,
      "last_update_posted_date": "2024-09-03",
      "last_synced_at": "2026-09-28T02:19:08.291Z",
      "location_count": 13,
      "location_summary": "Bakersfield, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Vero Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02422797"
    }
  ]
}